Recent advancements in lung cancer research: a narrative review
Top Cited Papers
Open Access
- 1 March 2025
- journal article
- review article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (3) , 975-990
Abstract
Background and Objective: Lung cancer remains the leading cause of cancer-related mortality worldwide, with a 5-year survival rate ranging from 10% to 20%. The majority of cases are categorized as non-small cell lung cancer (NSCLC) (80%) and small cell lung cancer (SCLC) (20%), with NSCLC being the more prevalent type. Tobacco use, particularly cigarette smoking, is a significant contributor to over 80% of lung cancer cases. Early diagnosis is challenging due to limitations in screening methods, resulting in many cases being identified only in advanced stages. Moreover, current treatment options often exhibit low efficacy, partly due to an inadequate understanding of the disease’s pathogenesis. This narrative review aims to summarize recent discoveries and advancements in lung cancer research, focusing on improvements in diagnosis, treatment, and understanding of the disease. Methods: A comprehensive literature review was performed utilizing the PubMed Central database to identify recent studies relevant to lung cancer. This review synthesizes findings from various research articles to provide a cohesive summary of advancements in the field. Key Content and Findings: In the past decade, notable progress has been achieved in lung cancer research, particularly concerning diagnostics and treatment strategies. Novel therapeutic approaches, including immunotherapy and genomic-targeted therapies, have demonstrated promising results. Understanding the tumor microenvironment (TME) and the role of T lymphocytes has become crucial for developing effective treatments. Additionally, advancements in immune checkpoint inhibitors (ICIs) have shown potential in enhancing patient outcomes. Improvements in tumor detection technologies are also anticipated to facilitate earlier diagnosis, ultimately contributing to better survival rates. Conclusions: Significant strides have been made in lung cancer research over the last ten years, particularly in diagnostics and treatment methodologies. Future research should prioritize exploring the TME, the function of T lymphocytes, and the efficacy of ICIs while continuing to innovate in tumor detection technologies. Such efforts are essential for enhancing treatment outcomes and improving the overall quality of life for lung cancer patients.Keywords
This publication has 142 references indexed in Scilit:
- Intratumoural chemotherapy of lung cancer for diagnosis and treatment of draining lymph node metastasisJournal of Pharmacy and Pharmacology, 2010
- Plasma DNA Quantification in Lung Cancer Computed Tomography ScreeningAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survivalEuropean Respiratory Journal, 2008
- Lung CancerNew England Journal of Medicine, 2008
- Postoperative Lung Function in Lung Cancer Patients: Comparative Analysis of Predictive Capability of MRI, CT, and SPECTAmerican Journal of Roentgenology, 2007
- Attitudes towards screening for lung cancer among smokers and their non-smoking counterpartsThorax, 2007
- Computer-Aided Detection in Screening CT for Pulmonary NodulesAmerican Journal of Roentgenology, 2006
- Intrapulmonary Administration of CCL21 Gene-Modified Dendritic Cells Reduces Tumor Burden in Spontaneous Murine Bronchoalveolar Cell CarcinomaCancer Research, 2006
- Quantification of Free Circulating DNA As a Diagnostic Marker in Lung CancerJournal of Clinical Oncology, 2003
- Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.1997